INDIVIDUALIZATION OF SPECIFIC MOLECULAR AND GENETIC CHANGES OF NSCLC PATIENTS WITH MOLECULAR GENETIC MUTATIONS IN THE KHANTY- MANSIYSK AUTONOMOUS DISTRICT — UGRA

Mordovskii A. A., Aksarin A. A., Troyan P. P., Kopeyka S. M., Pakhtusov A. I., Karabaev J.

The article presents clinicopathologic, gender, demographic and anamnestic characteristics of NSCLC patients with molecular genetic changes in Khanty-Mansiysk autonomous district-Ugra. The clinical material for the study consisted of 266 NSCLC patients. The characterization of mutations in EGFR, ALK, ROS1, BRAF, ERBB2 (HER2), KRAS, MET oncogenes, as well as PD-L1 expression level is presented. Lung adenocarcinoma showed the highest proportion of genetic aberrations - 33% (87/266), in comparison with other histologic subtypes - 6% (16/266). The relative chance of developing genetic aberrations in EGFR, KRAS, ALK oncogenes was 21.08; 9.04 and 10.84 times higher in lung adenocarcinomas; 15.87, 2.18 10.2 times higher among never smokers than in control groups, respectively. The relative chance of developing genetic alterations in EGFR and ALK oncogenes among those living in Yugra at the time of diagnosis ≥ 30 years was 0.42 and 0.31 times higher, than in the control group. PD-L1 expression status did not affect the frequency of genetic changes in EGFR, ALK, KRAS, and HER2 oncogenes.

Keywords:lung cancer, morbidity, mortality, adenocarcinoma, squamous cell cancer, biological marker, oncogene, molecular genetic diagnosis, target therapy